Ultra-low molecular weight collagen peptides at 300 to 500 Da, built for absorption, metabolic balance and glucose control.
Made by Sel Sanayi
Conventional collagen is a structural material. Through controlled enzymatic hydrolysis, CollaSel Tripeptide is reduced to short chains of three amino acids at 300 to 500 Da, the size window where peptides stop being mere nutrition and start acting as signals, absorbed intact and recognised by the body.
More than 80% of the fraction sits as di- and tripeptides within the PepT1 transport window, giving a monomodal, low-polydispersity profile (mean weight around 450 Da, PDI close to 1.1) that conventional hydrolysates cannot match.
Peptide bioactivity is not linear with size. It peaks in a narrow ultra-low molecular weight window, then falls away as peptides grow too large to be absorbed intact. CollaSel Tripeptide is engineered to sit exactly on that peak.
Tripeptides at 300 to 500 Da are carried across the intestinal wall intact through PepT1 (SLC15A1), a proton-coupled symporter, without the brush-border hydrolysis step that slows larger peptides. The result is saturable, carrier-mediated uptake that reaches a complete plateau at 240 minutes.
Saturable transport through PepT1 (SLC15A1), the proton-coupled intestinal symporter. T50 around 115 minutes, steady-state plateau by 240 minutes. High apparent permeability, Michaelis-Menten kinetics, tripeptides cross intact.
First-order uptake, rate-limited by brush-border peptidase hydrolysis. Apparent zero-order regime within 240 minutes, no saturation reached. Low intrinsic permeability.
Oligopeptides exceed the size cut-off of carrier transporters and depend on extensive paracellular and transcellular hydrolysis cascades before any uptake.
| Parameter | CollaSel Tripeptide · 300 to 500 Da | Standard · 2,000 Da | Standard · 5,000 Da |
|---|---|---|---|
| Absorption route | PepT1 carrier, intact | Hydrolysis then uptake | Paracellular and hydrolysis cascade |
| Kinetic order | Saturable, Michaelis-Menten | First-order to apparent zero-order | Diffusion-limited |
| Curve shape | Sigmoidal | Linear | Slow linear |
| T50, half-maximal | Around 115 min | Not reached, no plateau | Not reached, no plateau |
| Plateau, steady state | By 240 min | None within 240 min | None within 240 min |
| Cumulative at 240 min | 100% | 48% | 40% |
| Relative AUC index, 0 to 240 min | 100 | 37 | 30 |
| Apparent permeability | High | Low | Lowest |
More of every gram reaches circulation, so a given systemic exposure can be met with less material, relevant to cost in use and tablet or sachet load.
Half-maximal by around 115 minutes and a plateau by 4 hours support a sharper exposure peak rather than a slow, incomplete climb.
A defined transporter and a saturable plateau make the absorption profile consistent and easy to communicate to formulators and customers.
Model and scope. Curves and parameters depict cumulative apical-to-basolateral transport in a Caco-2 monolayer model and are intended for mechanistic comparison of molecular weight classes. Values illustrate the transport behaviour described, PepT1-mediated against hydrolysis and diffusion-limited uptake, and are not a substitute for clinical pharmacokinetic data. The AUC index is the area under each curve over 0 to 240 minutes by trapezoidal integration, normalised to Tripeptide equal to 100. PepT1 is SLC15A1, the proton-coupled di and tripeptide symporter.
CollaSel Tripeptide acts on three validated targets at once: it stimulates the incretin hormone GLP-1, inhibits the enzyme that degrades it, and modulates the enzyme that raises blood pressure.
Direct activation of enteroendocrine L cells, increasing post-meal release of active GLP-1, which promotes glucose-dependent insulin secretion and supports satiety.
Competitive inhibition of the enzyme that inactivates GLP-1 within minutes, prolonging incretin action and supporting post-meal glucose regulation.
Inhibition of the conversion of angiotensin I into the vasoconstrictor angiotensin II, encouraging vascular relaxation and balanced blood pressure.
High-resolution mass spectrometry mapped 1,683 peptides and predicted their biological activity. The tripeptide-enriched profile carries five times the bioactive sequence load of standard collagen.
| Bioactivity | CollaSel Tripeptide (500 Da) | Collagen peptides (2,000 Da) | Ratio |
|---|---|---|---|
| ACE inhibitor | 2,101 (32.8%) | 405 (34.9%) | 4x |
| DPP-IV inhibitor | 1,901 (29.7%) | 334 (28.8%) | 5x |
| Antithrombotic | 653 (10.2%) | 107 (9.2%) | 5x |
| Antioxidant | 99 (1.5%) | 26 (2.2%) | 3x |
| Anti-inflammatory | 7 (0.1%) | 0 (0%) | 7x |
| Total predicted bioactivity | 6,408 | 1,159 | 5x |
| Endpoint | Model | Result | Significance | Interpretation |
|---|---|---|---|---|
| GLP-1 secretion | STC-1 cells | +16.9% | p < 0.01 | Stimulates incretin release |
| DPP-IV inhibition | Enzyme assay, 1 mg/mL | −46.6% | p < 0.01 | Prolongs incretin activity |
| ACE inhibition | Enzyme assay, 1,035 µg/mL | −48.2% | p < 0.05 | Supports vascular tone |
| DPP-IV inhibition | Caco-2 cells, in situ | −8.1% | p < 0.05 | Confirms intestinal efficacy |
| Cell viability | MTT, Caco-2 and STC-1 | 95% or above | n.s. | Confirms cytocompatibility |
Consumer priorities are shifting from beauty to metabolic balance and inner vitality. As GLP-1 therapies reshape weight and glucose management, demand is rising for natural, science-backed ingredients that support metabolism without sacrificing muscle.
High solubility and a neutral taste make CollaSel Tripeptide ready for the products consumers are reaching for.
Ready-to-mix drinks and shots for glucose balance and daily metabolic support.
Powders and sticks that pair incretin support with muscle-sparing protein.
Formulas built around the ACE-modulating fraction for blood pressure balance.
Synergy with fibre and pre/probiotics along the gut to metabolism axis.
The original skin and joint benefit of collagen, in a faster-absorbed form.
Stable, neutral and easy to formulate across delivery formats.
More than 80% di- and tripeptides, the highest collagen tripeptide content available, confirmed by mass spectrometry.
GLP-1, DPP-IV and ACE activity published in Biomedicines 2026 and validated in human cell models.
Carried whole through PepT1 to reach a complete absorption plateau within 4 hours.
Produced in an accredited European facility, halal and kosher certified, with full traceability.
A Tezman Holding company
Sel Sanayi is a subsidiary of Tezman Holding, a leading Turkish industrial group founded in 1948. From a single product in 1961, it has grown into a science-led manufacturer of hydrocolloids, collagen, peptides, proteins and bioactive ingredients, supplied to brands in more than 40 countries.
What began in 1961 as technical gelatine from bovine hides is today a clinically studied collagen platform. Sel Sanayi controls the full chain, from raw material selection through hydrolysis, purification and grading, and produces CollaSel Tripeptide in its 2019 collagen factory in Edirne, accredited by the European Union.
Havsa, EdirneAlongside CollaSel collagen peptides, Sel Sanayi develops a range of high-value bioactives, each carrying the Sel mark and a single, science-backed benefit.
Hydrolyzed Type II collagen with chondroitin for joint support.
Polydeoxyribonucleotide that supports regeneration and collagen synthesis.
Collagen, elastin, hyaluronic acid and chondroitin for joints and beauty.
Palatability and organ nutrition, rich in heme iron and B vitamins.
Product quality and safety come first, with hazard analysis and risk management carried out in line with good manufacturing practices. The management system is established to FSSC 22000, ISO 9001:2015, ISO 22000:2018 and TS OIC/SMIIC 1:2019, with halal and kosher certification.
Every ingredient begins in our own laboratory, developed by a dedicated research and development team with a strong academic foundation.
Our research is led by scientists with a strong academic background, grounding every ingredient in rigorous method.
A dedicated team drives formulation, testing and validation, from first concept to finished ingredient.
Development takes place in our own laboratory, where new ingredients are designed, refined and validated.
Request a dossier, a sample or a specification sheet.
Hacıahmet Mahallesi, Irmak Caddesi No. 1-9, DLP İş Merkezi İç Kapı No.19
34440 Beyoğlu, Istanbul
Telephone: +90 212 253 62 40
Fax: +90 212 253 77 78
info@selsanayi.com
Yeni Mahallesi, Baglardere Mevkii No: 2
22500 Havsa, Edirne, Turkey
Telephone: +90 284 336 11 15 / +90 284 336 11 18
CollaSel Tripeptide is a food ingredient. The findings on this page are based on in vitro and in silico research and are intended for product developers and formulators. They are not intended to diagnose, treat, cure or prevent any disease. Health and nutrition claims used in finished consumer products must be adjusted to comply with the local regulatory framework, including Regulation (EC) No 1924/2006 in the European Union.